Holen Sie sich die Stockscreener-App
2.44
0.81%
-0.02
Handel nachbörslich:
2.48
0.04
+1.64%
Schlusskurs vom Vortag:
$2.46
Offen:
$2.41
24-Stunden-Volumen:
56,829
Relative Volume:
0.53
Marktkapitalisierung:
$11.12M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+10.41%
1M Leistung:
-2.40%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$2.39
$2.62
1-Wochen-Bereich:
$2.14
$2.65
52-Wochen-Spanne:
$1.89
$6.48
Newcelx Ltd Stock (NCEL) Company Profile
Vergleichen Sie NCEL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NCEL
Newcelx Ltd
|
2.44 | 11.21M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.92 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.92 | 79.26B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
813.24 | 49.47B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.26 | 48.47B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.29 | 38.37B | 4.98B | 69.59M | 525.67M | 0.5197 |
Newcelx Ltd Aktie (NCEL) Neueste Nachrichten
NewcelX Reports Positive International Study Results on Biomaterial-Based Islet Delivery for Type 1 Diabetes - TipRanks
NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression - PR Newswire
NLS Pharmaceutics Announces Reverse Share Split and Name Change Amid Merger - MSN
NewCelX Appoints EY as New Auditor Following Merger - MSN
NewcelX appoints Swiss pharma executive to scientific advisory board By Investing.com - Investing.com Nigeria
NewcelX adds Swiss diabetes leader to advisory board to steer IsletRx program - MSN
NewcelX Ltd. Announces Appointment Of Dr. Julien Boisdron To Scientific Advisory Board - marketscreener.com
NewcelX Adds Swiss Diabetes Leader to Advisory Board to Steer IsletRx Program - TipRanks
NewcelX appoints Swiss pharma executive to scientific advisory board - Investing.com
NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board - Barchart.com
NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board (2026-01-05) - Seeking Alpha
Should I buy NewcelX Ltd. (NCEL) - Zacks Investment Research
What is the current Price Target and Forecast for NewcelX Ltd. (NCEL) - Zacks Investment Research
NewcelX Ltd. (NCEL) Stock Forecast 2026, 2030 & 7-Year Price Prediction | Meyka AI - Meyka
NewcelX Strengthens IP Portfolio with Chinese Patent Publication - TipRanks
NewcelX strengthens IP portfolio with Chinese patent publication - MSN
NewcelX patent for neurological disease treatments published in China - Investing.com
NewcelX patent for neurological disease treatments published in China By Investing.com - Investing.com Canada
NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China - Nasdaq
NewcelX Ltd. (NCEL) -8.5% in After-hours: Decline Amid Routine Trading Conditions - Stocks Telegraph
NLSP SEC FilingsNls Pharmaceutics Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025 - Aktiellt
NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board (PR Newswire) - Aktiellt
NewcelX Ltd.Ordinary Shares (NQ: NCEL - Markets Financial Content
[6-K] NLS Pharmaceutics Ltd. Current Report (Foreign Issuer) | NLSP SEC FilingForm 6-K - Stock Titan
NewcelX appoints ALS specialist to scientific advisory board By Investing.com - Investing.com Nigeria
NewcelX appoints ALS specialist to scientific advisory board - Investing.com
NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute - Finviz
NewcelX Appoints Renowned Neurologist to Strengthen Scientific Advisory Board - TipRanks
Price to sales ratio of NewcelX Ltd. – NASDAQ:NCEL - TradingView
Press Release: NewcelX Announces Scientific Leadership With the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board - 富途牛牛
NewcelX Ltd. (NCEL) - Zacks Investment Research
NLS Pharmaceutics to execute 1-for-10 reverse share split - MSN
NewcelX Ltd. (NCEL) company profile and facts - Yahoo Finance UK
NewcelX Announces New CFO Appointment Following Merger - MSN
NewcelX Ltd. (NCEL) interactive stock chart - Yahoo Finance UK
NewcelX Ltd. (NCEL) Stock Forum & Discussion - Yahoo! Finance Canada
NewcelX Ltd (NCEL) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
NewcelX Ltd (NCEL) Stock Earnings Transcripts - GuruFocus
NewcelX appoints Omri Hagai as chief financial officer, effective December 10 By Investing.com - Investing.com Australia
NewcelX appoints Omri Hagai as chief financial officer, effective December 10 - Investing.com India
Neurology expert Prof. Ben-Hur joins NewcelX scientific board By Investing.com - Investing.com Nigeria
NewcelX Ltd. Revenue Breakdown – NASDAQ:NCEL - TradingView
NewcelX Ltd. (NCEL) analyst ratings, estimates and forecasts - Yahoo Finance Australia
NewcelX Ltd. (NCEL) Income Statement - Yahoo! Finance Canada
NewcelX Ltd. (NCEL) valuation measures and financial statistics - Yahoo Finance Australia
NCEL Interactive Stock Chart | NewcelX Ltd. Stock - Yahoo Finance
Finanzdaten der Newcelx Ltd-Aktie (NCEL)
Es liegen keine Finanzdaten für Newcelx Ltd (NCEL) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.67%
1.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):